Biophytis (EPA:ALBPS) | WebDisclosure

REGULATED PRESS RELEASE

published on 04/19/2024 at 07:00, 2 years 5 months ago

Biophytis annonce un changement de ratio pour son programme d'American Depositary Receipt (
Biophytis annonce un changement de ratio pour son programme d'American Depositary Receipt (ADR) le 23 avril 2024, entraînant un regroupement des ADS et une augmentation du prix de négociation

Biophytis American Depositary Receipt Changement De Ratio Regroupement D'ADS Prix De Négociation
REGULATED PRESS RELEASE

published on 04/19/2024 at 07:00, 2 years 5 months ago

Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program
Biophytis announces ratio change for its American Depositary Receipt program, affecting ADS to Shares ratio. No new shares issued, trading price may increase. Details provided in the press release

Biophytis Shares Ads American Depositary Receipt Ratio Change
BRIEF

published on 04/18/2024 at 07:05, 2 years 5 months ago

Biophytis crée un Conseil Scientifique pour son étude sur l'obésité

Biophytis Conseil Scientifique Étude Clinique BIO101 Obésité
BRIEF

published on 04/18/2024 at 07:05, 2 years 5 months ago

Biophytis Announces New Scientific Advisory Board for Phase 2 Obesity Study

Biophytis Scientific Advisory Board BIO101 Obesity OBA Clinical Study
PRESS RELEASE

published on 04/18/2024 at 07:02, 2 years 5 months ago

Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité
Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité. La société vise à soutenir l'avancement de la recherche avec des experts renommés du domaine de l'obésité

Biophytis Conseil Scientifique Étude Clinique Obésité Phase 2 OBA
PRESS RELEASE

published on 04/18/2024 at 07:02, 2 years 5 months ago

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
Biophytis appoints new Scientific Advisory Board for phase 2 OBA clinical study in obesity with Prof. Dennis Villareal and Prof. Francisco Guarner. IND filing with FDA soon

FDA Biophytis Scientific Advisory Board Obesity OBA Clinical Study
REGULATED PRESS RELEASE

published on 04/18/2024 at 07:00, 2 years 5 months ago

Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité
Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité, avec dépôt d'IND auprès de la FDA dans les prochaines semaines

FDA Biophytis Conseil Scientifique Étude Clinique Obésité
REGULATED PRESS RELEASE

published on 04/18/2024 at 07:00, 2 years 5 months ago

Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
Biophytis forms new Scientific Advisory Board for phase 2 OBA clinical study in obesity, including Professor Dennis Villareal and Professor Francisco Guarner. IND filing with FDA imminent

Biophytis Scientific Advisory Board Obesity Phase 2 OBA Clinical Study IND Filing
BRIEF

published on 04/15/2024 at 07:05, 2 years 5 months ago

Biophytis annonce une nouvelle demande de brevet dans le domaine de l'obésité

Biophytis Propriété Intellectuelle BIO101 Obésité Demande De Brevet
BRIEF

published on 04/15/2024 at 07:05, 2 years 5 months ago

Biophytis Enhances Intellectual Property in Obesity Treatment with New Patent Application

Biophytis Pharmaceuticals Patent Application BIO101 Obesity

Published on 09/23/2026 at 18:25, 2 hours 5 minutes ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 4 hours 48 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 5 hours 59 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 6 hours ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
Published on 09/23/2026 at 14:00, 6 hours 30 minutes ago

Integrated Rewards Launches "Celebrate Canadian" Campaign to Connect Canadian Brands with Millions of Consumers

View all ACCESSWIRE

Published on 09/23/2026 at 19:51, 38 minutes ago

LIGHTON: LightOn renouvelle son financement obligataire auprès des mêmes partenaires financiers pour un montant nominal maximum de 4 millions d’euros, et étend ainsi son horizon de trésorerie
Published on 09/23/2026 at 19:51, 38 minutes ago

LIGHTON: LightOn renews its bond financing with the same financial partners for a maximum nominal amount of €4 million, and thus extends its cash flow horizon
Published on 09/23/2026 at 19:30, 1 hour ago

EUROPLASMA: Valdunes Industries et Saarstahl Ascoval s’associent pour développer une nouvelle génération de « roues vertes »
Published on 09/23/2026 at 18:05, 2 hours 24 minutes ago

XPRIZE Wildfire Awards $4.55M to Innovators Advancing Wildfire Detection and Response
Published on 09/23/2026 at 18:00, 2 hours 29 minutes ago

ARVERNE GROUP: Release of the 2026 half-year financial report

View all EQS

Published on 09/23/2026 at 19:46, 43 minutes ago

SFPI GROUP: half year 2026 results
Published on 09/23/2026 at 19:46, 43 minutes ago

SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 1 hour 15 minutes ago

Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 19:14, 1 hour 15 minutes ago

Performance robuste des Investissements, poursuite du déploiement de la stratégie
Published on 09/23/2026 at 18:00, 2 hours 30 minutes ago

CIS : H1 2026 results.

View all LES ECHOS COMFI WIRE

News